Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | PNMT | P11086 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2965705 | 0.87 | TRPA1 (0.36) | RAPGEF4ADRA2APNMTADRA2BADRA2C | |
| SCHEMBL4269308 | 0.78 | PTGS2 (0.46) | ALDH1A1MEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL2973732 | 0.73 | ALDH1A1 (0.37) | ADRA2APNMTADRA2BADRA2CALDH1A1 | |
| SCHEMBL2974276 | 0.72 | ALDH1A1 (0.38) | ADRA2APNMTADRA2BADRA2CALDH1A1 | |
| SCHEMBL2964136 | 0.71 | CYP11B1 (0.42) | PNMTALDH1A1CYP11B1CYP11B2 | |
| SCHEMBL2973643 | 0.70 | RAPGEF4 (0.31) | RAPGEF4ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL2962318 | 0.70 | TRPA1 (0.34) | RAPGEF4ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL2965972 | 0.68 | METAP1 (0.39) | RAPGEF4ADRA2APNMTADRA2BADRA2C | |
| SCHEMBL2965031 | 0.67 | KMT2A (0.35) | ALDH1A1MEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL2964034 | 0.67 | PIK3R1 (0.42) | ALDH1A1NPSR1MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763562-B2 | Heteroatom bridged metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070135597-A1 | Heteroatom bridged metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135597-A1 | Heteroatom bridged metallocene compounds for olefin polymerization | AP2M1, AP1M1, PYM1 | RAPGEF4 1250/4885ADRA2A 2587/4885PNMT 2021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.